Renal Cancer
暂无分享,去创建一个
Umberto Capitanio | Francesco Montorsi | U. Capitanio | F. Montorsi | Rodrigo Pessoa | Fernando J. Kim | F. Montorsi | Rodrigo Pessoa | Fernando J. Kim
[1] Ricardo A Rendon,et al. Active surveillance as the preferred management option for small renal masses. , 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[2] D. Parekh,et al. Tolerance of the human kidney to isolated controlled ischemia. , 2013, Journal of the American Society of Nephrology : JASN.
[3] T. Wilt,et al. Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.
[4] Walter Artibani,et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. , 2009, European urology.
[5] S. Horenblas,et al. Feasibility of sentinel node detection in renal cell carcinoma: a pilot study , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[6] P. Tamboli,et al. Partial nephrectomy in the setting of metastatic renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Makarewicz,et al. The value of postoperative radiotherapy in advanced renal cell cancer. , 1998, Neoplasma.
[8] W. Meinhardt,et al. Intraoperative sentinel node identification and sampling in clinically node-negative renal cell carcinoma: initial experience in 20 patients , 2011, World Journal of Urology.
[9] E. Sacco,et al. Paraneoplastic Syndromes in Patients with Urological Malignancies , 2009, Urologia Internationalis.
[10] E. Messing,et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. , 2014, European urology.
[11] W Marston Linehan,et al. New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease , 2015, Clinical Cancer Research.
[12] P. Albers,et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. , 2007, The Journal of urology.
[13] M. Lacouture,et al. Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. , 2014, Clinical genitourinary cancer.
[14] C. la Vecchia,et al. History of treated hypertension and diabetes mellitus and risk of renal cell cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] D. Jacqmin,et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. , 2009, European urology.
[16] John C Bischof,et al. The cryobiology of cryosurgical injury. , 2002, Urology.
[17] R. Sylvester,et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. , 2011, European urology.
[18] G. Sonpavde,et al. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial. , 2014, Future oncology.
[19] M. Staehler,et al. Local treatments for metastases of renal cell carcinoma: a systematic review. , 2014, The Lancet. Oncology.
[20] K. Katsanos,et al. Systematic Review and Meta-Analysis of Thermal Ablation Versus Surgical Nephrectomy for Small Renal Tumours , 2014, CardioVascular and Interventional Radiology.
[21] N. Munshi,et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.
[22] A. Evans,et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. , 2011, European urology.
[23] B. Rini,et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Klatte,et al. Associations Between Presenting Symptoms, Clinicopathological Parameters, and Prognosis in a Contemporary Series of Patients With Renal Cell Carcinoma , 2014, Korean journal of urology.
[25] P. Russo,et al. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. , 2008, The Urologic clinics of North America.
[26] Lauren McCann,et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.
[27] R. Uzzo,et al. Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. , 2008, The Journal of urology.
[28] R. Sylvester,et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. , 2013, European urology.
[29] R. Sylvester,et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. , 2007, European urology.
[30] R. Flanigan,et al. New modalities for evaluation and surveillance of complex renal cysts. , 2014, The Journal of urology.
[31] N. Vogelzang,et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.
[32] U. Capitanio,et al. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. , 2010, Urology.
[33] C. Wood,et al. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy , 2014, World Journal of Urology.
[34] C. Tangen,et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.
[35] E. Maher,et al. VHL, the story of a tumour suppressor gene , 2014, Nature Reviews Cancer.
[36] Antonio Lopez-Beltran,et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.
[37] R. Uzzo,et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Robert G. Uzzo,et al. Heterogeneity and renal mass biopsy: a review of its role and reliability , 2014, Cancer biology & medicine.
[39] Lorenzo Marconi,et al. EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.
[40] R. Uzzo,et al. Focal therapy for treatment of the small renal mass: dealer's choice or a therapeutic gamble? , 2015, European urology.
[41] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Robert G Uzzo,et al. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. , 2009, The Journal of urology.
[43] R. Sylvester,et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.
[44] J. Patard,et al. A comparative population‐based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma , 2010, BJU international.
[45] L. Jones,et al. Recent advances in imaging cancer of the kidney and urinary tract. , 2014, Surgical oncology clinics of North America.
[46] Apurva A Desai,et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] R. Uzzo,et al. Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. , 2014, The Journal of urology.
[48] Marco Bianchi,et al. Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift , 2012, Annals of Surgical Oncology.
[49] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[50] Birt-Hogg-Dubé syndrome. , 2013, JAMA.
[51] W. Marston Linehan,et al. Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors , 2011, PLoS genetics.
[52] Inderbir S Gill,et al. Kidney tumor location measurement using the C index method. , 2010, The Journal of urology.
[53] J. Patard,et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] D. Gervais,et al. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. , 2005, AJR. American journal of roentgenology.
[55] Y. Funahashi,et al. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. , 2009, European urology.
[56] C. Gross,et al. The Effect of the Diffusion of the Surgical Robot on the Hospital-level Utilization of Partial Nephrectomy , 2015, Medical care.
[57] A. Ravaud,et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] P. Boracchi,et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] R. Thompson,et al. Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. , 2015, European urology.
[60] S. Hancock,et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[61] S. Rosenberg,et al. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] P Kirkbride,et al. Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).
[63] W. Oyen,et al. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. , 2013, European urology.
[64] D. Burr,et al. Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study , 2008, BMC Cancer.
[65] A. Volpe,et al. Can emerging level 1 evidence "discourage" elective nephron-sparing surgery for small renal tumors? , 2011, European urology.
[66] T. Watnick,et al. Not all renal cysts are created equal , 2010, The Lancet.
[67] T. Delea,et al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. , 2015, Journal of managed care & specialty pharmacy.
[68] R. Motzer,et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] T. Choueiri,et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.
[70] C. Porta,et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[71] C. Porta,et al. Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial , 2008 .
[72] Stephanie Daignault,et al. Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect , 2006 .
[73] S. Karami,et al. A prospective study of alcohol consumption and renal cell carcinoma risk , 2015, International journal of cancer.
[74] Paul Russo,et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? , 2009, The Journal of urology.
[76] D. Bottaro,et al. Hereditary papillary renal carcinoma type I. , 2004, Current molecular medicine.
[77] R. Uzzo,et al. Is anatomic complexity associated with renal tumor growth kinetics under active surveillance? , 2015, Urologic oncology.
[78] N. Rioux-Leclercq,et al. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.
[79] M. Remzi,et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours. , 2012, European urology.
[80] N. Agarwal,et al. Sequencing Systemic Therapies for Metastatic Kidney Cancer , 2015, Current Treatment Options in Oncology.
[81] R. Figlin,et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] J. Brugarolas. PBRM1 and BAP1 as novel targets for renal cell carcinoma. , 2013, Cancer journal.
[83] A. Evans,et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. , 2011, European urology.
[84] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[85] U. Capitanio,et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. , 2015, European urology.
[86] M. Blute,et al. Surgery for renal cell carcinoma metastases , 2010, Current opinion in urology.
[87] B. Rini,et al. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.
[88] J. Patard,et al. Lymph node dissection in renal cell carcinoma. , 2011, European urology.
[89] K. Rha,et al. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. , 2015, European urology.
[90] C. Porta,et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] J. Bissler. Everolimus for renal angiomyolipoma in tuberous sclerosis , 2013 .
[92] E. Small,et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] Han Yong Choi,et al. The epidemiology of renal cell carcinoma. , 2011, European urology.
[94] R. Motzer,et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.
[95] W. Lowrance,et al. Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder Contemporary Use of Partial Nephrectomy at a Tertiary Care Center in the United States , 2022 .
[96] B. Lane,et al. Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease. , 2013, The Journal of urology.
[97] J. Manola,et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] Jacques Ferlay,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .
[99] Lisa M. Schwartz,et al. Are increasing 5-year survival rates evidence of success against cancer? , 2000, JAMA.
[100] R. Uzzo,et al. Delayed intervention of sporadic renal masses undergoing active surveillance , 2008, Cancer.
[101] F. Saad,et al. Radical versus partial nephrectomy , 2009, Cancer.
[102] J. Himmelfarb,et al. Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib , 2014 .
[103] F. Marshall. Obesity and Renal Cell Cancer—a Quantitative Review , 2002 .
[104] V. Khoo,et al. Radiotherapy for renal-cell carcinoma. , 2014, The Lancet. Oncology.
[105] J. Patard,et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. , 2008, Urology.
[106] P. Cairns,et al. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC , 2013, Epigenetics.
[107] A. Wein,et al. Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. , 1994, Radiology.
[108] Mark W. Ball,et al. Grade heterogeneity in small renal masses: potential implications for renal mass biopsy. , 2015, The Journal of urology.
[109] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[110] J. Lam,et al. Kidney cancer management in 2004: An update for the practicing general urologist , 2004, Current urology reports.
[111] M. Bader,et al. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron‐sparing surgery in patients with renal cell carcinoma , 2009, BJU international.
[112] R. Motzer,et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] W. Linehan,et al. Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. , 2013, The Journal of urology.
[114] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] W. Samlowski,et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] I. Derweesh,et al. Trends in the surgical management of localized renal masses: thermal ablation, partial and radical nephrectomy in the USA, 1998–2008 , 2013, BJU international.
[117] R. Miano,et al. Robotic radical nephrectomy for renal cell carcinoma: a systematic review , 2014, BMC Urology.
[118] R. Sega,et al. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. , 2007, Current drug safety.
[119] R. Motzer,et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] J. Bellmunt,et al. SEOM clinical guidelines for the treatment of renal cell carcinoma , 2014, Clinical and Translational Oncology.
[121] J. Ferlay,et al. The changing pattern of kidney cancer incidence and mortality in Europe , 2008, BJU international.
[122] Paul Russo,et al. Commentary on The R.E.N.A.L. nephrometry score: A comprehensive standardized system for quantitating renal tumor size, location and depth , 2010 .
[123] Mark W. Ball,et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. , 2015, European urology.
[124] A. Kuten,et al. The value of postoperative irradiation in renal cell cancer. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[125] M. Gordon,et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .
[126] David C. Miller,et al. Partial nephrectomy for small renal masses: an emerging quality of care concern? , 2006, The Journal of urology.
[127] J. Brugarolas,et al. Sirolimus in metatastic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] A. Hemal,et al. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. , 2007, The Journal of urology.
[129] John T. Wei,et al. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? , 2006, Urology.
[130] J. Cheville,et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. , 2015, European urology.
[131] U. Vaishampayan. Cabozantinib as a Novel Therapy for Renal Cell Carcinoma , 2013, Current Oncology Reports.